Journal article

PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes

HR Ali, S-E Glont, FM Blows, E Provenzano, S-J Dawson, B Liu, L Hiller, J Dunn, CJ Poole, S Bowden, HM Earl, PDP Pharoah, C Caldas



BACKGROUND: Expression of programmed death ligand 1 (PD-L1) in solid tumours has been shown to predict whether patients are likely to respond to anti-PD-L1 therapies. To estimate the therapeutic potential of PD-L1 inhibition in breast cancer, we evaluated the prevalence and significance of PD-L1 protein expression in a large collection of breast tumours. PATIENTS AND METHODS: Correlations between CD274 (PD-L1) copy number, transcript and protein levels were evaluated in tumours from 418 patients recruited to the METABRIC genomic study. Immunohistochemistry was used to detect PD-L1 protein in breast tumours in tissue microarrays from 5763 patients recruited to the SEARCH population-based stud..

View full abstract


Awarded by Cancer Research UK

Awarded by Academy of Medical Sciences (AMS)

Awarded by Medical Research Council

Awarded by National Institute for Health Research

Awarded by The Francis Crick Institute

Funding Acknowledgements

This work was supported by Cancer Research UK (C490/A10119 and C490/A10124), the Cambridge Experimental Cancer Medicine Centre and the NIHR Cambridge Biomedical Research Centre. HRA is an NIHR Academic Clinical Lecturer and supported by a Career Development Fellowship from the Pathological Society of Great Britain and Northern Ireland and a Starter Grant for Clinical Lecturers from the Academy of Medical Sciences, UK.